Trial Profile
Clinical safety and activity of pembrolizumab monotherapy in previously-treated patients with advanced non-small cell lung cancer (NSCLC)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Nov 2015
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Merck & Co
- 30 Nov 2015 New trial record